Rethink Priorities recently conducted an independent analysis of GOAL 3's evidence base on IMPALA. To correct for study design and robustness of findings, they applied a 60% internal-validity and a 30% external-validity discount to measured mortality effects, arriving at roughly 12% for paediatric wards and 7% for neonatal units, and still found IMPALA at $7–17 and $12–30 per DALY averted.

Rethink also calculated cost-effectiveness around the threshold from Givewell and Coefficient Giving showing around 76× and 28× unconditional cash transfers against GiveWell's 6× bar, for paedeatrics and neonatal respectively, and roughly 11,700× and 4,400× on Coefficient Giving's scale against their 1,000× bar. Their own report states: "the conclusion holds because the intervention is inexpensive rather than because the effect is large. At roughly $2–6 per child admitted per year, the break-even is a 1% relative reduction in mortality." According to the report even with a discounted rate of 12% and 7% reduction in mortality IMPALA remains highly cost-effective because of how affordable the solution is.

‍GOAL 3 and Rethink Priorities will explore what this report means for the EA world, whether patient monitoring could really be this effective, or whether it is too good to be true. If you would like to read the report you can find it here.